New CRISPR method could take gene editing to the next level – New Scientist
|
New CRISPR method could take gene editing to the next level
New Scientist The CRISPR genome-editing method may just have become even more powerful. Uri David Akavia’s team at McGill University in Canada has managed to repair mutations in 90 per cent of target cells using CRISPR – the best success rate yet. The CRISPR … |
SMA News Today |
AveXis Expands Clinical Testing of Gene Therapy, AVXS-101, to Include Milder SMA Types
SMA News Today AveXis plans to launch clinical trials of its gene therapy AVXS-101 in a wider range of spinal muscular atrophy (SMA) patients — mirroring the company’s belief that the treatment may also benefit those with milder forms of the disease. The planned … Insider Selling: AveXis Inc (AVXS) Insider Sells 15000 Shares of StockThe Ledger Gazette AveXis Inc. (AVXS) Soars 5.05% on January 18Equities.com AveXis Inc (AVXS) VP James J. Litalien Sells 5000 SharesDispatch Tribunal The Lincolnian Online –TrueBlueTribune all 26 news articles » |
|
The European Patent Office Revokes the Broad Institute’s CRISPR Patents
Labiotech.eu (blog) The Broad Institute has been stripped of the first of its CRISPR/Cas9 patents by the European Patent Office due to previous publications outdating its work. CRISPR/Cas9 has been hailed as the ‘scientific discovery of the century’ due to its capacity to … |